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ARTICLE
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Mucopolysaccharidosis IIIC (MPS IIIC, or Sanﬁlippo C syndrome) is a lysosomal storage disorder caused by the inherited
deﬁciency of the lysosomal membrane enzyme acetyl–coenzyme A:a-glucosaminide N-acetyltransferase (N-acetyltrans-
ferase), which leads to impaired degradation of heparan sulfate. We report the narrowing of the candidate region to a
2.6-cM interval between D8S1051 and D8S1831 and the identiﬁcation of the transmembrane protein 76 gene (TMEM76),
which encodes a 73-kDa protein with predicted multiple transmembrane domains and glycosylation sites, as the gene
that causes MPS IIIC when it is mutated. Four nonsense mutations, 3 frameshift mutations due to deletions or a dupli-
cation, 6 splice-site mutations, and 14 missense mutations were identiﬁed among 30 probands with MPS IIIC. Functional
expression of human TMEM76 and the mouse ortholog demonstrates that it is the gene that encodes the lysosomal N-
acetyltransferase and suggests that this enzyme belongs to a new structural class of proteins that transport the activated
acetyl residues across the cell membrane.
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Heparan sulfate is a polysaccharide found in proteogly-
cans associated with the cell membrane in nearly all cells.
The lysosomal membrane enzyme, acetyl–coenzyme A
(CoA):a-glucosaminideN-acetyltransferase (N-acetyltrans-
ferase) is required to N-acetylate the terminal glucosamine
residues of heparan sulfate before hydrolysis by the a-N-
acetyl glucosaminidase. Since the acetyl-CoA substrate
would be rapidly degraded in the lysosome,1 N-acetyl-
transferase employs a unique mechanism, acting both
as an enzyme and a membrane channel, and catalyzes
the transmembrane acetylation of heparan sulfate.2 The
mechanism by which this is achieved has been the topic
of considerable investigation, but, for many years, the iso-
lation and cloning of N-acetyltransferase has been ham-
pered by its low tissue content, instability, and hydro-
phobic nature.3–5
Genetic deﬁciency of N-acetyltransferase causes muco-
polysaccharidosis IIIC (MPS IIIC [MIM 252930], or San-
ﬁlippo syndrome C), a rare autosomal recessive lysosomal
disorder of mucopolysaccharide catabolism.6–8 MPS IIIC is
clinically similar to other subtypes of Sanﬁlippo syn-
drome.9 Patients manifest symptoms during childhood
with progressive and severe neurological deterioration
causing hyperactivity, sleep disorders, and loss of speech
accompanied by behavioral abnormalities, neuropsychi-
atric problems, mental retardation, hearing loss, and rel-
atively minor visceral manifestations, such as mild he-
patomegaly, mild dwarﬁsm with joint stiffness and
biconvex dorsolumbar vertebral bodies, mild coarse faces,
and hypertrichosis.7 Most patients die before adulthood,
but some survive to the 4th decade and show progressive
dementia and retinitis pigmentosa. Soon after the ﬁrst 3
patients with MPS IIIC were described by Kresse et al.,6
Klein et al.8,10 reported a similar deﬁciency in 11 patients
who had received the diagnosis of Sanﬁlippo syndrome,
therefore suggesting that the disease is a relatively fre-
quent subtype. The birth prevalence of MPS IIIC in Aus-
tralia,11 Portugal,12 and the Netherlands13 has been esti-
mated to be 0.07, 0.12, and 0.21 per 100,000, respectively.
The putative chromosomal locus of the MPS IIIC gene
was ﬁrst reported in 1992. By studying two siblings who
received the diagnosis of MPS IIIC and had an apparently
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balanced Robertsonian translocation, Zaremba et al.14 sug-
gested that the mutant gene may be located in the peri-
centric region of either chromosome 14 or chromosome
21, but no further conﬁrmation of this ﬁnding was pro-
vided. Previously, we performed a genomewide scan on
27 patients with MPS IIIC and 17 unaffected family mem-
bers, using 392 highly informative microsatellite markers
with an average interspacing of 10 cM. For chromosome
8, the scan showed an apparent excess of homozygosity
in patients compared with their unaffected relatives.15 Ad-
ditional genotyping of 38 patients with MPS IIIC for 22
markers on chromosome 8 identiﬁed 15 consecutive
markers (from D8S1051 to D8S2332) in an 8.3-cM interval
for which the genotypes of affected siblings were identical
in state. A maximum multipoint LOD score of 10.6 was
found at marker D8S519, suggesting that this region in-
cludes the locus for MPS IIIC.15 Recently, localization of
the MPS IIIC causative gene on chromosome 8 was con-
ﬁrmed bymicrocell-mediated chromosome transfer in cul-
tured skin ﬁbroblasts of patients with MPS IIIC.16
Here, we report the results of linkage analyses that nar-
rowed the candidate region for MPC IIIC to a 2.6-cM in-
terval between D8S1051 and D8S1831 and the identiﬁ-
cation of the TMEM76 gene, located within the candidate
region, as the gene that codes for the lysosomal N-ace-
tyltransferase and, when mutated, is responsible for MPS
IIIC.
Material and Methods
Families
In Montreal, 33 affected individuals and 35 unaffected relatives
comprising 15 families informative for linkage were genotyped.
The families came from Europe, North Africa, andNorth America.
An additional 27 affected individuals and 9 unaffected relatives
in uninformative pedigrees, as well as 40 controls, were also ge-
notyped. Eleven of these families and the controls have been
reported elsewhere.15 In addition, 54 individuals from four MPS
IIIC–affected families from the Czech Republic were studied in
Prague (ﬁg. 1). One family had two affected brothers, whereas
the remaining three families each had one affected individual.
The families came from various regions of the Czech Republic
and were not related within the four most-recent generations.
The diagnosis for affected individuals was conﬁrmed by the mea-
surement of N-acetyltransferase activity in cultured skin ﬁbro-
blasts or white blood cells.
Genotyping
The samples in Montreal were genotyped for 22 microsatellite
markers in the pericentromeric region of chromosome8 spanning
8.9 cM on the Rutgers map, version 2.0.17 The genotyping was
performed as described by Mira et al.18 at the McGill University
and Genome Quebec Innovation Centre on an ABI 3730xl DNA
Analyzer platform (Applied Biosystems). Alleles were assigned us-
ing Genotyper, version 3.6 (Applied Biosystems). The random-
error model of SimWalk2, version 2.91,19,20 was used to detect
potential genotyping errors, with an overall error rate of 0.025.
Nine genotypes for which the posterior probability of being in-
correct was 10.5 were removed before subsequent analyses. In
addition, nine genotypes for one marker in one family were re-
moved because of a suspected microsatellite mutation. The sam-
ples from the Czech Republic were genotyped in Prague for 18
microsatellite markers in an 18.7-cM region that includes the 8.9-
cM region mentioned above. The genotyping was performed on
an LI-COR IR2 sequencer by use of Saga genotyping software (Li-
Cor) as described elsewhere.21 Genotypes were screened for errors
by use of the PedCheck program.22
Linkage Analysis
For the families genotyped in Montreal, multipoint linkage anal-
ysis was performed using the Markov chain–Monte Carlo
(MCMC)method implemented in SimWalk2, version 2.91,19 since
one pedigree was too large to be analyzed by exact computation.
A fully penetrant autosomal recessive parametric model was used
with a disease-allele frequency of 0.0045. Marker-allele frequen-
cies were estimated by counting alleles in the available parents
of patients with MPS IIIC and in control individuals. To check
the consistency of the results, the MCMC analysis was repeated
four times.
N-acetyltransferase activity was measured in all participants of
the four families from the Czech Republic.23 Individualswere clas-
siﬁed as affected, carriers, or unaffected on the basis of the results
of this assay. Mean affected and carrier activities were determined
from the ﬁve affected individuals and their seven obligate het-
erozygote parents, respectively, whereas themean control activity
was determined from a sample of 89 unrelated individuals. Four
individuals were unable to be classiﬁed because their values were
within 2 SDs of the means of both the control and carrier groups.
Multipoint linkage analysis was performed using a codominant
model with a penetrance of 0.99 and a phenocopy rate of 0.01,
to account for the possibility of misclassiﬁcation or genotyping
errors. The same disease-allele frequency of 0.0045 was used.
Marker-allele frequencies were estimated by counting all geno-
typed individuals. Exact multipoint linkage analysis was run on
18 microsatellite markers by use of Allegro 1.2c,24 which was also
used to infer haplotypes.
Gene-Expression Analysis
For each of 32 genes located in the candidate interval, a single
5′-amino–modiﬁed 40-mer oligonucleotide probe (Illumina) was
spotted in quadruplicate on aminosilane-modiﬁed microscopic
slides and was immobilized using a combination of baking and
UV cross-linking. Total RNA (250–1,000 ng) from white blood
cells of two patients with MPS IIIC (patients AIV.8 and BIII.5) and
four healthy individuals were ampliﬁed using the SenseAmp plus
RNA Ampliﬁcation Kit (Genisphere) and were reverse transcribed
using 300 ng of poly(A)-tailed mRNA. Reverse transcription and
microarray detection were done using the Array 900 Expression
Detection Kit (Genisphere) according to the manufacturer’s pro-
tocol. The two patient samples and four control samples were
analyzed in dye-swap mode, in two replicates of each mode. The
hybridized slides were scanned with a GenePix 4200A scanner
(Molecular Devices), with photomultiplier gains adjusted to ob-
tain the highest-intensity unsaturated images. Data analysis was
performed in the R statistical environment (The R Project for
Statistical Computing, version 2.2.1) by use of the Linear Models
for Microarray Data package (Limma, version 2.2.0).25 Raw data
were processed using loess normalization and a moving mini-
mum background correction on individual arrays and quantile
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Figure 1. Four families from the Czech Republic used in the linkage and mutation analyses. Fully blackened symbols indicate individuals
with MPS IIIC; arrowheads indicate probands. Measurements in seven obligate heterozygotes from these pedigrees (mean  SD 11.6
 1.5 nmol/h/mg) and 89 controls not known to be related to members of the pedigree (mean  SD 24.4  5.7 nmol/h/mg) were
used to establish N-acetyltransferase activity ranges for heterozygotes (symbols with blackened inner circle) and normal homozygotes
(open symbols). An individual was assigned to a class if his or her enzyme activity was within 2 SDs of the class, unless the value was
within the overlap of the upper end of the obligate heterozygotes and the lower end of the controls. Individuals with values within
the open interval 13.0–14.6 nmol/h/mg were classiﬁed as unknown (symbols with gray inner circle). A symbol with a question mark
(?) indicates that no material was available for the enzyme assay. DNA was available for individuals with ID numbers, and N-acetyl-
transferase activity measurements in white blood cells are shown below the ID numbers.
normalization between arrays. The correlation between four du-
plicate spots per gene on each array was used to increase the
robustness. A linear model was ﬁtted for each gene given a series
of arrays by use of the lmFit function. The empirical Bayes
method26 was used to rank the differential expression of genes
by use of the eBayes function. Correction for multiple testingwas
performed using the Benjamini and Hochberg false-discovery–
rate method.27 We considered genes to be differentially expressed
if the adjusted P value was !.01.
DNA and RNA Isolation and Sequencing
Cultured skin ﬁbroblasts from patients with MPS IIIC and normal
controls were obtained from cell depositories (Hoˆpital Debrousse,
Figure 2. Multipoint linkage analysis of MPS IIIC on chromosome 8. A, Multipoint LOD scores in an 8.9-cM interval from two sets of
families. Symbols above the marker names indicate the map position. Marker names are listed in the correct order but may be displaced
from the symbols for visibility. The dashed line is based on families genotyped in Montreal, and the dotted line on families genotyped
in Prague. Straight lines next to marker names indicate that the markers were typed in both data sets. Triangles pointing down indicate
markers typed only in the Montreal data set, and triangles pointing up indicate markers typed only in the Prague data set. For the
Montreal data, the SimWalk2 run with the highest likelihood is shown. TMEM76 lies between D8S1115 and D8S1460, and, according to
the March 2006 freeze of the human genome sequence from the University of California–Santa Cruz Genome Browser,30 the order is
D8S1115–(500 kb)–TMEM76–(800 kb)–centromere–(200 kb)–D8S1460. B, Multipoint LOD scores from the Montreal data from four runs
of SimWalk2, version 2.91,19 showing the variation between runs.
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Figure 3. Predicted amino acid sequence of the TMEM76 protein. Amino acid sequence alignment of Homo sapiens TMEM76 with
orthologs from Mus musculus (cloned sequence), Canis familiaris (GenBank accession number XP_539948.2), Bos taurus (XP_588978.2),
Rattus norvegicus (XP_341451.2), and Pan troglodytes (XP_519741.1) by use of BLAST. All cDNA sequences are predicted except the
sequence for M. musculus. The identical residues are boxed, the residues with missense mutations in patients with MPS IIIC are shown
in red, and the amino acid changes are indicated above the sequence. The ﬁrst 67 aa of the human sequence shown as black on yellow
comprise the predicted signal peptide. The predicted transmembrane domains in the human sequence are shown as black on turquoise.
The topology model5–7 strongly predicts that the N-terminus is inside the lysosome and the C-terminus is outside. Four predicted N-
glycosylation sites are shown as black on pink, and the predicted motifs for the lysosomal targeting, as black on green.
France; NIGMSHumanGeneticMutant Cell Repository;Montreal
Children’s Hospital, Canada; and Department of Clinical Genet-
ics, Erasmus Medical Center, The Netherlands). Blood samples
from patients with MPS IIIC, their relatives, and controls were
collected with ethics approval from the appropriate institutional
review boards. DNA from blood or cultured skin ﬁbroblasts was
extracted using the PureGene kit (Gentra Systems). Total RNA
from cultured skin ﬁbroblasts and pooled tissues (spleen, liver,
kidney, heart, lung, and brain) of a C57BL/6J mouse was isolated
using Trizol (Invitrogen), and ﬁrst-strand cDNA synthesis was pre-
pared with SuperScript II (Invitrogen). DNA fragments containing
TMEM76 exons and adjacent regions (∼40 bp from each side;
primer sequences are shown in appendix A) were ampliﬁed by
PCR from genomic DNA and were puriﬁed with Montage PCR96
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Figure 4. Volcano plot of genes located within the MPS IIIC candidate region, showing signiﬁcantly reduced expression of the TMEM76
gene in white blood cells of two patients with MPS IIIC: AIV.8 and BIII.5. The natural logarithm of the probability that the gene is
differentially expressed (Log odds) is plotted as a function of the logarithm of the gene-expression log2 fold change (Log fold change)
between the patient and control samples.
Figure 5. Northern-blot analysis of TMEM76 mRNA in human tis-
sues. A 12-lane blot containing 1 mg of poly A RNA per lane
from various adult human tissues was hybridized with a [32P]-
labeled 220-bp cDNA fragment corresponding to exons 8–10 of
the TMEM76 gene or b-actin, as described in the Material and
Methods section.
ﬁlter plates (Millipore). Each sequencing reaction contained 2 ml
of puriﬁed PCR product, 5.25 ml of H2O, 1.75 ml of 5# sequencing
buffer, 0.5 ml of 20 mM primer, and 0.5 ml of Big Dye Terminator
v3.1 (all from Applied Biosystems). In Montreal, PCR products
were analyzed using an ABI 3730xl DNA Analyzer (Applied Bio-
systems). In Prague, PCR products were analyzed on an ALFex-
press DNA sequencer (Pharmacia), as described elsewhere.28 In-
cluded in the sequencing analysis were 30 probands with MPS
IIIC who were considered unrelated and 105 controls. The con-
trols were unrelated CEPH individuals, and ampliﬁed DNAs were
combined in pools of two before sequencing.
Northern Blotting
A 12-lane multiple-tissue northern blot containing 1 mg of poly
A RNA per lane from various human tissues (BD Biosciences
Clontech) was hybridized with the 220-bp cDNA fragment cor-
responding to exons 8–10 of the human TMEM76 gene or the
entire cDNA of human b-actin labeled with [32P]-dCTP by random
priming with the MegaPrime labeling kit (Amersham). Prehybri-
dization of the blot was performed at 68C for 30 min in
ExpressHyb (Clontech). The denatured probeswere addeddirectly
to the prehybridization solution and were incubated at 68C for
1 h. The blots were washed twice for 30 min at room temperature
with 2# sodium chloride–sodium citrate (SSC) solution and
0.05% SDS and once for 40 min at 50C with 0.1# SSC and 0.1%
SDS and were exposed to a BioMax ﬁlm for 48 h.
Mouse and Human TMEM76 cDNA Cloning
Mouse coding sequence was ampliﬁed by PCR (forward primer
5′-GAATTCATGACGGGCGGGTCGAGC-3′; reverse primer 5′-
ATATGTCGACGATTTTCCAAAACAGCTTC-3′) and was cloned
into pCMV-Script, pCMV-Tag4A (Stratagene), and pEGFP-N3 (BD
Biosciences Clontech) vectors by use of the EcoRI and SalI restric-
tion sites of the primers. The cloned sequence was identical to
GenBank accession number AK152926.1, except that an “AT”was
needed to complete an alternate ATG initiation codon. GenBank
accession number AK149883.1 provides what we consider to be
the complete clone and encodes a 656-aa protein. The GenBank
sequences differ by 1 aa and three silent substitutions.
A 1,907-bp fragment of the human TMEM76 cDNA (nt 75 to
1992) was ampliﬁed using Platinum High Fidelity Taq DNA
polymerase (Invitrogen), a sense primer with an HindIII site (5′-
AAGCTTGGCGGCGGGCATGAG-3′), and an antisense primer
with an SalI site (5′-GTCGACCTCAGTGGGAGCCATCAGATTTT-
3′) and was cloned into pCMV-Script expression vector (Strata-
gene). Since high GC content (85%) of the 5′ region of human
TMEM76 cDNA prevented its ampliﬁcation by PCR, a synthetic
186-bp codon-optimized double-stranded oligonucleotide frag-
ment (5′-AAGCTTATGACCGGAGCGAGGGCAAGCGCCGCCG-
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AACAAAGAAGAGCCGGACGGTCCGGCCAGGCTAGGGCCGC-
AGAGCGAGCTGCTGGCATGTCAGGTGCAGGGCGCGCACTTG-
CCGCCTTGCTGCTCGCCGCGAGTGTGCTGAGCGCTGCCCTC-
CTGGCTCCCGGAGGCTCTTCCGGGCGGGAC-3′) correspond-
ing to nt 1 to 186 of human TMEM76 cDNA was purchased
from BioS&T. A 177-bp 5′ fragment was combined with rest of
the cDNA by use of HindIII and SapI sites. The cloned sequence
is identical to GenBank accession number XM_372038.4 from nt
131 to nt 1946, except for the presence of SNP rs1126058.
Cell Culture and Transfection
Skin ﬁbroblasts and COS-7 cells were cultured in Eagle’s minimal
essential medium (Invitrogen) supplemented with 10% (v/v) fetal
bovine serum (Invitrogen) and were transfected with the full-size
mouse Tmem76 (Hgsnat) coding sequence subcloned into pCMV-
Script, pCMV-Tag4A, and pEGFP-N3 vectors or with the full-size
human TMEM76 coding sequence subcloned into pCMV-Script
vector by use of Lipofectamine Plus (Invitrogen) according to the
manufacturer’s protocol. The cells were harvested 48 h after trans-
fection, and N-acetyltransferase activity was measured in the ho-
mogenates of TMEM76-transfected and mock-transfected cells
(i.e., transfected with only the cloning vector).
Enzyme Assay
N-acetyltransferase enzymatic activity was measured using the
ﬂuorogenic substrate 4-methylumbelliferyl b-D-glucosaminide
(Moscerdam) as described elsewhere.23 Protein concentrationwas
measured according to the method of Bradford.29 This assay was
used for the activity measurements in cultured skin ﬁbroblasts or
white blood cells from patients and all participating members of
the Czech families and for the functional expression experiments.
Confocal Microscopy
To establish colocalization of the tagged protein with the lyso-
somal compartment, the skin ﬁbroblasts expressing mouse
TMEM76-EGFP were treated with 50 nM LysoTracker Red DND-
99 dye (Molecular Probes), were washed twice with ice-cold PBS,
and were ﬁxed with 4% paraformaldehyde in PBS for 30 min.
Slides were studied on an LMS 510 Meta inverted confocal mi-
croscope (Zeiss).
Results
Linkage Analysis
Previously, we performed a genomewide linkage study
that indicated that the locus for MPS IIIC is mapped to
an 8.3-cM interval in the pericentromeric region of chro-
mosome 8.15 To reduce this interval, we genotyped the
families from that study as well as newly obtained MPS
IIIC–affected families for 22 microsatellite markers (Mon-
treal data). Linkage analysis under an autosomal recessive
model resulted in LOD scores 114 in the 4.2-cM region
spanning D8S1051 to D8S601, which included the cen-
tromere (ﬁg. 2). The results of multiple MCMC runs
showed consistent trends. Linkage was also performed in
four families from the Czech Republic by use of an au-
tosomal codominant model (Prague data). For these data,
linkage analysis produced a maximum LOD score of 7.8
at 66.4 cM at D8S531 and reduced the linked region for
the Montreal data to a 2.6-cM interval between D8S1051
and D8S1831. This region was deﬁned by inferred recom-
binants at D8S1051 in one family in each of the Montreal
and Prague data sets, and a recombinant at D8S1831 in
an additional family in the Prague data set. This interval
contains 32 known or predicted genes and ORFs.
Identiﬁcation of a Candidate Gene
On the basis of our previous studies that deﬁned the mo-
lecular properties of the lysosomal N-acetyltransferase,31
we searched the candidate region for a gene encoding
a protein with multiple transmembrane domains and
a molecular weight of ∼100 kDa, which allowed us to
exclude the majority of the genes in the region. In con-
trast, the predicted protein product of the TMEM76 gene
has multiple putative transmembrane domains. The pre-
dicted coding region in GenBank accession number
XM_372038.4 was extended by 28 residues at the 5′ end
on the basis of the transcript in GenBank accession num-
ber DR000652.1 (which includes 14 of the 28 residues),
examination of the genomic sequence in NT_007995.14,
and comparison with mouse sequence AK149883.1. We
predict that the modiﬁed TMEM76 contains 18 exons, cor-
responding to an ORF of 1,992 bp, and codes for a 73-kDa
protein. A comparison of human TMEM76 with ﬁve ver-
tebrate orthologs is shown in ﬁgure 3. Furthermore, of all
the genes present in the candidate interval, only TMEM76
showed a statistically signiﬁcant reduction of the tran-
script level in the cells of two patients withMPS IIIC (AIV.8
and BIII.5; adjusted P values ! .001) in the custom oli-
gonucleotide-based microarray assay (ﬁg. 4). Further, we
showed that both patients carried nonsense mutations
presumably causing mRNA decay (R534X and L349X; see
table 2).
Analysis of the TMEM76 Transcript by Northern Blot
and RT-PCR
Northern-blot analysis identiﬁed twomajorTMEM76 tran-
scripts of 4.5 and 2.1 kb ubiquitously expressed in various
human tissues (ﬁg. 5). The highest expressionwas detected
in leukocytes, heart, lung, placenta, and liver, whereas the
gene was expressed at a much lower level in the thymus,
colon, and brain, which is consistent with the expression
patterns of lysosomal proteins. Consistent with the north-
ern-blot results, a full-length 4.5-kb cDNA containing
1,992 bp of coding sequence and two polyadenylation
signals as well as two shorter transcripts were ampliﬁed
by RT-PCR from the total RNA of normal human skin
ﬁbroblasts, white blood cells, and skeletal muscle. In one
transcript, exons 9 and 10 were spliced out, leading to an
in-frame deletion of 64 aa, which contains the predicted
transmembrane domains III and IV. Most likely, this tran-
script does not encode an active enzyme, since it was also
detected in the RNA of two patients with MPS IIIC (pa-
tients CIII.1 and CIII.2) who had almost complete loss of
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Table 1. Mutations in TMEM76 Identiﬁed in Patients from 30 Families
with MPS IIIC
Mutation Group
and Mutationa
Predicted Effect
on Protein
No. of
Alleles
Location
in TMEM76
Nonsense mutations:
c.1031GrA p.W344X 2 Exon 10
c.1046TrG p.L349X 1 Exon 10
c.1234CrT p.R412X 8 Exon 12
c.1600CrT p.R534X 1 Exon 15
Missense mutations:
c.311GrT p.C104F 1 Exon 2
c.932CrT p.P311L 3 Exon 9
c.1114CrT p.R372C 3 Exon 11
c.1115GrA p.R372H 1 Exon 11
c.1354GrA p.G452S 2 Exon 13
c.1495GrA p.E499K 3 Exon 14
c.1529TrA p.M510K 1 Exon 14
c.1706CrT p.S569L 4 Exon 17
c.1769ArT p.D590V 1 Exon 17
c.1796CrT p.P599L 1 Exon 17
Frameshift mutations:
c.1118_1133del p.I373SfsX3 1 Exon 11
c.1420_1456dup p.V488GfsX22 1 Exon 13
c.1834delG p.V612SfsX16 1 Exon 18
Splice-site mutations:
c.2021GrA p.L69EfsX32b 1 Intron 1
c.5771GrA p.P193HfsX20b 1 Intron 4
c.9355GrA p.F313X 1 Intron 9
c.13341GrA p.G446Xb 1 Intron 12
c.18101GrA p.S567NfsX14 2 Intron 17
Complex mutations:
c.[3181GrA; 794CrA] p.[D68VfsX19; P265Q] 6 Intron 2; exon 7
c.[5771GrA; 1650ArC] p.[P193HfsX20; K551Q] 2 Intron 4; exon 16
c.[1293GrT; 1927GrA] p.[W431C; A643T] 2 Exon 12; exon 18
a Mutation names were assigned according to the guidelines of the Human Genome Variation
Society and on the basis of the cDNA sequence from GenBank accession number NT_007995.14,
except that the ﬁrst exon includes 84 nt 5′ of the stated ATG initiation codon. Thus, 1
corresponds to the A of the ATG at nt 13315945 (instead of nt 13316029).
b The mutations were named under the assumption that no exon skipping takes place; cDNA
sequencing was not done.
N-acetyltransferase activity. Another transcript lacked ex-
ons 3, 9, and 10.
The deduced amino acid sequence predicts 11 trans-
membrane domains and four potential N-glycosylation
sites (ﬁg. 3), consistent with the molecular properties of
lysosomal N-acetyltransferase.31 The ﬁrst 67 aa may com-
prise the signal peptide, with length and composition re-
sembling those of lysosomal proteins. According to the
predictions made by empirical computer algorithms,32–34
the C-terminus of the TMEM76 protein is exposed to the
cytoplasm and contains conserved Tyr-X-X-V and Leu-Leu
sequencemotifs involved in the interactionwith the adap-
tor proteins responsible for the lysosomal targeting of
membrane proteins.35
Mutation Analysis
We identiﬁed 27 TMEM76 mutations in the DNA of 30
MPS IIIC–affected families (table 1) that were not found
in DNA from 105 controls. Among the identiﬁed muta-
tions, there were 4 nonsense mutations, 14 missense mu-
tations, 3 predicted frameshift mutations due to deletions
or duplications, and 6 splice-site mutations. All the mis-
sense mutations occur at residues conserved among ﬁve
species with the most homologous TMEM76 sequences
(ﬁg. 3), except for P265Q, which is not conserved in the
mouse, and W431C, which is not conserved in the rat.
There were three instances of two mutations on the same
allele that were found in patients who were homozygous,
and these are designated as complex mutations in table
1. cDNA sequencing of one of the patients homozygous
for the splice-site mutation in intron 2 and a missense
mutation (P265Q) demonstrated that the splice-site mu-
tation disrupts the consensus splice-site sequence between
exon 2 and intron 2 and causes exon 2 skipping and a
frameshift (not shown).
Consanguinity was reported in 4 of the 13 families in
which the patients were homozygous for TMEM76 mu-
tations: the two Moroccan families, the French family
with two missense mutations (W431C and A643T), and
the Turkish family with the splice-site mutation in intron
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Table 2. TMEM76 Predicted Mutations in Probands from 30 Families with MPS IIIC
Patient Group and Mutation 1 Mutation 2
No. of
Patients
Geographic Origin
of Patient(s)
Patients from Czech families:
p.I373SfsX3 p.R534X 1 Czech Republic
p.L349X p.M510K 1 Czech Republic
p.F313X p.R412X 1 Czech Republic
p.R372H p.P599L 1 Czech Republic
Patients homozygous for TMEM76 mutations:
p.[D68VfsX19; P265Q] p.[D68VfsX19; P265Q] 3 Morocco, Morocco, and Spain
p.[P193HfsX20; K551Q] p.[P193HfsX20; K551Q] 1 France
p.P311L p.P311L 1 United Kingdom
p.W344X p.W344X 1 France
p.R372C p.R372C 1 United Kingdom
p.R412X p.R412X 2 Turkey and Poland
p.[W431C; A643T] p.[W431C; A643T] 1 France
p.G452S p.G452S 1 Canada
p.E499K p.E499K 1 Canada
p.S567NfsX14 p.S567NfsX14 1 Turkey
Patients compound heterozygous for TMEM76 mutations:
p.C104F … 1 Belarus
p.E499K p.D590V 1 France
p.P193HfsX20 p.R412X 1 Canada
p.P311L p.R372C 1 France
p.R412X … 1 Poland
p.R412X p.G446X 1 Poland
p.S569L … 2 France and Portugal
p.S569L p.L69EfsX32 1 United States
p.V488GfsX22 p.S569L 1 Poland
p.V612SfsX16 … 1 Finland
Families with no mutations identiﬁed to date … 2 North Africa and Portugal
17. The two Moroccan families were not known to be
related to each other or to the Spanish patient homozy-
gous for the same mutations (table 2). The parents of the
French patient are second cousins in two ways (see family
F1 in the work of Ausseil et al.15).
The splice-site mutation in the above-mentioned Turk-
ish family disrupts the consensus splice-site sequence be-
tween exon 17 and intron 17 and causes exon 17 skipping
and a frameshift in all transcripts, as detected by sequenc-
ing of multiple RT-PCR clones (not shown). The two af-
fected siblings in this family (family F8 in the work of
Ausseil et al.15) had a severe form of MPS IIIC and showed
almost complete loss of N-acetyltransferase activity in cul-
tured skin ﬁbroblasts. Among other severely affected pa-
tients with MPS IIIC, a patient of French origin was ho-
mozygous for a nonsense mutation (W344X) in exon 10,
which may result in the synthesis of a truncated protein
or RNA decay. A patient of Polish origin was a compound
heterozygote for a 37-bp duplication in exon 13 and a
missense mutation (S569L) in exon 17 (table 2). The du-
plication results in a frameshift, whereas the substitution
of a strictly conserved small polar Ser for a bulky hydro-
phobic Leu may have a signiﬁcant structural impact (ﬁg.
3).
The ﬁve patients from four Czech families are all com-
pound heterozygotes for eight different mutations (table
2). Five of the eight mutations are predicted to result in
truncated products (three nonsense mutations, one 16-bp
deletion, and one splice-site mutation leading to the in-
clusion of 89 bases from the 5′ end of intron 9 and the
splicing out of exon 10 in the transcript, and the remain-
ing three are missense mutations affecting residues con-
served among multiple species and located either in the
predicted transmembrane regions (ﬁg. 3) or in their close
vicinity, suggesting that theymay have a serious structural
impact. In the Czech families, the mutations completely
segregated with reduced enzyme activity. That is, all in-
dividuals assigned to be heterozygotes on the basis of the
enzyme assay as well as the four individuals who were
within 2 SD of the lower end of the controls (symbols
with gray inner circle in ﬁg. 1) were found to carry
TMEM76 mutations.
Functional Expression Studies
The ﬁbroblast cell line from a patient homozygous for a
splice-site mutation in intron 17 with negligible N-ace-
tyltransferase activity was transfected with plasmids con-
taining human TMEM76 cDNA or cDNA of the mouse
ortholog of TMEM76 carrying a FLAG tag on the C-ter-
minus or of a fusion protein of mouse TMEM76 with en-
hanced green ﬂuorescent protein (EGFP). All constructs
increased the N-acetyltransferase activity in the mutant
ﬁbroblast cells to approximately normal level (ﬁg. 6A).
Signiﬁcant increase in activity was also observed in trans-
fected COS-7 cells, conﬁrming that the TMEM76 protein
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Figure 6. Functional expression of human and mouse TMEM76 protein. A, The full-size human and mouse TMEM76 coding sequences
subcloned into pCMV-Script, pCMV-Tag4A, and pEGFP-N3 vectors were expressed in COS-7 cells and in cultured skin ﬁbroblasts from a
patient with MPS IIIC. The cells were harvested 48 h after transfection, and N-acetyltransferase activity was measured in the homogenates
of TMEM76-transfected and mock-transfected ﬁbroblast or COS-7 cells by use of the artiﬁcial ﬂuorometric substrate 4-methylumbelliferyl-
b-D-glucosaminide.23 Values represent means  SD of four independent experiments. B, The intracellular localization of TMEM76 was
studied by expressing the fusion protein of the mouse TMEM76 with EGFP. Before ﬁxation, the cells were treated for 45 min with 50
nM lysosomal marker, LysoTracker Red DND-99 dye. Slides were analyzed on an LMS 510 Meta confocal microscope (Zeiss). Magniﬁcation
#1000. The image was randomly selected from 30 studied panels, all of which showed a similar localization of TMEM76-EGFP. The
ﬂuorescence of EGFP was not quenched as it would have been if the ﬂuorophore had been exposed to the acidic lysosomal microen-
vironment, conﬁrming that the C-terminus of TMEM76 faces the cytoplasmic side of the lysosomal membrane.
by itself has N-acetyltransferase activity. Confocal ﬂuores-
cent microscopy shows that TMEM76-EGFP (ﬁg. 6B) or
TMEM-FLAG (not shown) peptides are targeted in human
ﬁbroblasts to cytoplasmic organelles, colocalizingwith the
lysosomal-endosomal marker LysoTracker Red.
Discussion
Degradation of heparan sulfate occurs within the lyso-
somes by the concerted action of a group of at least eight
enzymes: four sulfatases, three exo-glycosydases, and one
N-acetyltransferase, which work sequentially at the ter-
minus of heparan sulfate chains, producing free sulfate
and monosaccharides. The inherited deﬁciencies of four
enzymes involved in the degradation of heparan sulfate
cause four subtypes of MPS III: MPS IIIA (heparan N-sul-
fatase deﬁciency [MIM 252900]), MPS IIIB (a-N-acetylglu-
cosaminidase deﬁciency [MIM 252920]), MPS IIIC (acetyl-
CoA:a-glucosaminide acetyltransferase deﬁciency), and
MPS IIID (N-acetylglucosamine 6-sulfatase deﬁciency
[MIM 252940]). Since the clinical phenotypes of all these
disorders are similar, precise diagnosis relies on the deter-
mination of enzymatic activities in patients’ cultured skin
ﬁbroblasts or leukocytes. The biochemical defect in MPS
IIIC was identiﬁed 30 years ago as a deﬁciency of an en-
zyme that transfers an acetyl group from cytoplasmically
derived acetyl-CoA to terminal a-glucosamine residues of
heparan sulfate within the lysosomes, resulting in the ac-
cumulation of heparan sulfate. Therefore, for identiﬁca-
tion of the molecular basis of this disorder, we used two
complementary approaches. First, we performed a partial
puriﬁcation of human and mouse lysosomal N-acetyl-
transferase, which suggested that the enzyme has prop-
erties of an oligomeric transmembrane glycoprotein, with
an ∼100-kDa polypeptide containing the enzyme active
site.31 Second, by linkage analysis, we narrowed the locus
for MPC IIIC to a 2.6 cM-interval (D8S1051–D8S1831)
and, third, compared the level of transcripts of the genes
present in the candidate region between normal control
cells and those from patients with MPS IIIC. Thus, an in-
tegrated bioinformatic search and gene-expression anal-
ysis both pinpointed a single gene, TMEM76, which en-
codes a 73-kDa protein with predicted multiple trans-
membrane domains and glycosylation sites. DNA muta-
tion analysis showed that patients with MPS IIIC harbor
TMEM76 mutations incompatible with the normal func-
tion of the predicted protein, whereas expression of hu-
man TMEM76 and the mouse ortholog proved that the
protein has N-acetyltransferase activity and lysosomal lo-
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calization, providing evidence that TMEM76 is the gene
that codes for the lysosomal N-acetyltransferase.
The TMEM76 protein does not show a structural simi-
larity to any known prokaryotic or eukaryotic N-acetyl-
transferases or to other lysosomal proteins, on the basis
of sequence homology searches. Thus, we think that it
belongs to a new structural class of proteins capable of
transporting the activated acetyl residues across the cell
membrane. Moreover, TMEM76 shares homology with a
conserved family of bacterial proteins COG4299 (unchar-
acterized protein conserved in bacteria) (Entrez Gene
GeneID 138050). All 146 members of this family are pre-
dicted proteins from diverse bacterial species, including
Proteobacteria, Cyanobacteria, and Deinococci. Since
many of these bacteria are capable of synthesizingheparan
sulfate and other structurally related glycosaminoglycans
and perform reactions of transmembrane acetylation, it is
tempting to speculate that this activity may also be per-
formed by the proteins of the COG4299 family. Previous
studies suggested two contradictory mechanisms of trans-
membrane acetylation. Bame and Rome2,36,37 proposed
that it is performed via a ping-pong mechanism. First, the
acetyl group of acetyl-CoA is transferred to an His residue
in the active site of the enzyme. This induces a confor-
mational change that results in the translocation of the
protein domain containing the acetylated residue to the
lysosome, where the acetyl residue is transferred to the
glucosamine residue of heparan sulfate. In contrast, Mei-
kle et al.38 were unable to demonstrate any speciﬁc acet-
ylation of the lysosomal membranes and proposed an al-
ternative mechanism that involved the formation of a
tertiary complex of the enzyme, acetyl-CoA, and heparan
sufate. Identiﬁcation of N-acetyltransferase as a 73-kDa
protein with multiple transmembrane domains, together
with our previous data that showed that N-acetyltrans-
ferase is acetylated by [14C]acetyl-CoA in the absence of
glucosamine,31 strongly supports the ping-pong mecha-
nism of transmembrane acetylation.
For 23 of the 30 probands included in this study for
mutation analysis, TMEM76 mutations were identiﬁed in
both alleles. Five probands were heterozygous for a mis-
sense mutation, with a second mutation yet to be iden-
tiﬁed. In two probands from North Africa and Portugal,
we did not identify any mutations in the coding regions
or immediate ﬂanking regions. These patients are ho-
mozygous for the microsatellite markers throughout the
entire MPS IIIC locus and may be homozygous for a yet-
to-be-identiﬁed TMEM76 mutation; however, we cannot
formally exclude defects in other genes. Additional studies
have been initiated to search for mutations in the introns
and promoter regions. The patients with MPS IIIC with
the identiﬁed frameshift and nonsense mutations all have
a clinically severe early-onset form. The almost complete
deﬁciency of N-acetyltransferase activity in cultured skin
ﬁbroblasts from these patients is consistent with the pre-
dicted protein truncations and/or nonsense-mediated
mRNA decay. Further expression studies are necessary to
conﬁrm the impact of the identiﬁed substitutions of the
conserved amino acids on enzyme activity. Nevertheless,
the identiﬁcation of the lysosomal N-acetyltransferase
gene which, when mutated, accounts for the molecular
defect in patients with MPS IIIC sets the stage for DNA-
based diagnosis and genotype-phenotype correlation
studies and marks the end of the gene-discovery phase for
lysosomal genetic enzymopathies.
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Appendix A
Table A1. Exon-Flanking Primers Used for PCR
Ampliﬁcation and Sequencing of the Exons in the
Human TMEM76 Gene
Primer
Sequence
(5′r3′)
TMEM76_Exon1_F CTCCCGAAGACAAACACTCC
TMEM76_Exon1_R GCGAAGTCGCAGCAACAGC
TMEM76_Exon2_F AAGCTTTTGAGAAGCACTACTGG
TMEM76_Exon2_R GAAGGGCTTTAGACATGAGAGC
TMEM76_Exon3_F GGAAAAGTCATGTCAGGATCTCC
TMEM76_Exon3_R GAATAATACATGTTCCTGGGTACG
TMEM76_Exon4_F TTATTCTGCCTCCATGATATTAGC
TMEM76_Exon4_R CTACAGAAAGCGTCATGGACTGC
TMEM76_Exon5_F GGAAATTCAGCATGAGAATATAGG
TMEM76_Exon5_R GCCACTTGAGGGTGACAGC
TMEM76_Exon6_F GAATATGAGCTTTAATTTTATTTCC
TMEM76_Exon6_R TTAGGAATACGGGAGCTACAACC
TMEM76_Exon7_F CAAAATGAAATTTACCCCTTAGC
TMEM76_Exon7_R ACATCCAAGAAATCCTTCCTAGC
TMEM76_Exon8_F CCTTCCTTTTCACATAGCAAACC
TMEM76_Exon8_R GCTCTGTGAAGGACGTATATAAGC
TMEM76_Exon9_F CCCCTGGGTTTACTTTCTATACC
TMEM76_Exon9_R CCAGCATCATCTGAAAAACAGG
TMEM76_Exon10_F GGGGCTATATTCTGAACTCTTCC
TMEM76_Exon10_R ACCTGAGATGGAGGAATTGC
TMEM76_Exon11_F CTGGGATGAGAGGAGAAGTCC
TMEM76_Exon11_R ACTTGAAGCCAGGAGTGAGG
TMEM76_Exon12_F CCTTCTATTTGCATTTAGTTCACC
TMEM76_Exon12_R GAGAATTCCTCTGACTCGAGACC
TMEM76_Exon13_F TTTTATTCTTGTCCCTCTGTTCG
TMEM76_Exon13_R CACTTCTGAAAGCCTGAGTTCC
TMEM76_Exon14_F TTGGTCTAGGAGCTGTTTGTACG
TMEM76_Exon14_R CCATAGCACAAGAGAGAATATGC
TMEM76_Exon15_F TCTTTGTCAGGTAGTTAAGACAGTGG
TMEM76_Exon15_R GTGAAGGAAAGGAATTTTAGC
TMEM76_Exon16_F ACAAGTTTCAGCCCTCTCTACG
TMEM76_Exon16_R GTGGAGGAGACGTTTCAGTGC
TMEM76_Exon17_F ATGCTGAAATTGGATTTGTTCC
TMEM76_Exon17_R ACCAAGGATGCTCCAGAGG
TMEM76_Exon18_F AGTAGCCAACAATGGAAGTGC
TMEM76_Exon18_R GAGCCGTGTCACAGTTAACC
NOTE.—For bidirectional sequencing on the ALFexpress
DNA sequencer, all primers have the universal overhang syn-
thesized on the 5′ end (AATACGACTCACTATAG for forward [F]
primers and CAGGAAACAGCTATGAC for reverse [R] primers).
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
BLAST, http://www.ncbi.nlm.nih.gov/blast/ (used to identify or-
tholog protein sequences)
Entrez Gene, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dbp
gene (for GeneID 138050)
GenBank, http://www.ncbi.nih.gov/Genbank/ (for accession
numbers AK152926.1, AK149883.1, DR000652.1,XM_372038.4,
NT_007995.14, XP_539948.2, XP_588978.2, XP_341451.2, and
XP_519741.1)
Human Genome Variation Society, http://www.hgvs.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MPS IIIA, IIIB, IIIC, and IID)
The R Project for Statistical Computing,http://www.r-project.org/
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